DE69517302D1 - Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen - Google Patents

Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen

Info

Publication number
DE69517302D1
DE69517302D1 DE69517302T DE69517302T DE69517302D1 DE 69517302 D1 DE69517302 D1 DE 69517302D1 DE 69517302 T DE69517302 T DE 69517302T DE 69517302 T DE69517302 T DE 69517302T DE 69517302 D1 DE69517302 D1 DE 69517302D1
Authority
DE
Germany
Prior art keywords
verotoxin
pharmaceutical compositions
medical treatments
neoplastic
verotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69517302T
Other languages
English (en)
Other versions
DE69517302T2 (de
Inventor
Clifford A Lingwood
Richard Hill
Hannah Farkas-Himsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GEVA RUTH
KROYANKER LEORAH
Original Assignee
GEVA RUTH
KROYANKER LEORAH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GEVA RUTH, KROYANKER LEORAH filed Critical GEVA RUTH
Application granted granted Critical
Publication of DE69517302D1 publication Critical patent/DE69517302D1/de
Publication of DE69517302T2 publication Critical patent/DE69517302T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69517302T 1994-02-22 1995-02-20 Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen Expired - Lifetime DE69517302T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002116179A CA2116179C (en) 1994-02-22 1994-02-22 Verotoxin pharmaceutical compositions and medical treatments therewith
PCT/CA1995/000085 WO1995022349A1 (en) 1994-02-22 1995-02-20 Verotoxin pharmaceutical compositions and medical treatments therewith

Publications (2)

Publication Number Publication Date
DE69517302D1 true DE69517302D1 (de) 2000-07-06
DE69517302T2 DE69517302T2 (de) 2001-01-18

Family

ID=4152948

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69517302T Expired - Lifetime DE69517302T2 (de) 1994-02-22 1995-02-20 Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen

Country Status (10)

Country Link
US (1) US6228370B1 (de)
EP (1) EP0746337B1 (de)
JP (1) JPH10500103A (de)
AT (1) ATE193451T1 (de)
AU (1) AU701100B2 (de)
CA (1) CA2116179C (de)
DE (1) DE69517302T2 (de)
ES (1) ES2149347T3 (de)
NZ (1) NZ331165A (de)
WO (1) WO1995022349A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835710B1 (en) 1994-02-22 2004-12-28 Hsc Research & Development Limited Partnership Verotoxin pharmaceutical compositions and medical treatments therewith
WO1998051326A1 (en) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition of angiogenesis by verotoxins
PT1079856E (pt) 1998-05-20 2006-12-29 Pdl Biopharma Inc Anticorpos humanizados que reconhecem a verotoxina ii e linha celular que os produz
WO2000061183A2 (en) * 1999-04-09 2000-10-19 Hsc Research And Development Limited Partnership Verotoxin treatment of lymphomas
WO2000066714A2 (en) * 1999-05-03 2000-11-09 The Governors Of The University Of Alberta Shiga-like toxin as an enriching and purging agent
US20050163807A1 (en) 2002-02-04 2005-07-28 Xiaoyan Liu Anticancer agents using vero toxin variants

Also Published As

Publication number Publication date
CA2116179C (en) 2008-01-08
EP0746337A1 (de) 1996-12-11
ES2149347T3 (es) 2000-11-01
DE69517302T2 (de) 2001-01-18
AU1703195A (en) 1995-09-04
NZ331165A (en) 2000-01-28
CA2116179A1 (en) 1995-08-23
US6228370B1 (en) 2001-05-08
EP0746337B1 (de) 2000-05-31
ATE193451T1 (de) 2000-06-15
JPH10500103A (ja) 1998-01-06
WO1995022349A1 (en) 1995-08-24
AU701100B2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
FI884013A0 (fi) Konjugat av cytokiner med immunoglobuliner.
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
GEP20022804B (en) Erythropoietin Derivatives
PT933995E (pt) Metodo para tratamento de lesao endotelial
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
MX9708800A (es) Compuestos biciclicos aromaticos.
ES2033021T3 (es) Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
DE3685696D1 (de) Melatoninhaltige mittel sowie deren verwendungen.
DE69517302D1 (de) Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen
DE69734574D1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
ATE141510T1 (de) Arzneimittel enthaltend cd14
CA2163716A1 (en) Verotoxin pharmaceutical compositions and medical treatments therewith
ATE83657T1 (de) Pharmazeutische zusammensetzung.
RU94024337A (ru) Антиметастатическое средство
RU94021815A (ru) Способ лечения злокачественных новообразований
PT1150981E (pt) Composto nucleosidico terapeutico
KR0177821B1 (en) Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans
RU94001389A (ru) Способ лечения псориаза
RU94016144A (ru) Средство для лечения больных болезнью рейтера
JPS62242671A (ja) 癌の治療薬
UA23985A (uk) Спосіб лікуваhhя запальhих захворюваhь вhутрішhіх геhіталій у дівчат та підлітків

Legal Events

Date Code Title Description
8364 No opposition during term of opposition